A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).
Epistemonikos ID: 075ea88af84929cdbcf174dcf15d5d7d7a8d3800
First added on: Mar 19, 2021